Phase 1Status unknown
Evaluation of Ascorbate-Meglumine Therapeutic for SRS
Phase 1, Single-Center, Dose-Escalating, Open-Label, Safety Clinical Trial of Parenteral Ascorbate-Meglumine As a Novel Magnetic Resonance Imaging (MRI)-guided Adjunctive Therapeutic for Stereotactic Radiosurgery (SRS)
- Sponsor
- LadeRx LLC (Industry)
- Enrolment
- 12 planned
- Conditions
- Safety
- Interventions
- Ascorbate-Meglumine
- Ages
- adults, older adults
- Registry
- NCT06433791
Full record on ClinicalTrials.gov
From the registry
Phase 1, Single-Center, Dose-Escalating, Open-Label, Safety Clinical Trial of Parenteral Ascorbate-Meglumine as a Novel Magnetic Resonance Imaging (MRI)-guided Adjunctive Therapeutic for Stereotactic Radiosurgery (SRS)
Primary outcomes
- Safety as measured by adverse events
History
Study completion
Primary completion
Last registry update
Started
Registered